Using individual patient data we found strong evidence of benefit across endpoints: PFS, radiographic PFS (rPFS), and castration resistance free survival (CRFS). Overall survival (OS) barely missed significance with P=0.051 in the mixed effect model
Examining guidelines on radiotherapy for #BladderCancer with carcinoma in situ. @ConstanceHuck joins @UroDocAsh to examine whether carcinoma in situ should contraindicate trimodality therapy for muscle-invasive bladder cancer. The conversation highlights how historical data showing poor outcomes with CIS may be outdated, as older studies used split-course radiotherapy and inferior imaging techniques. #WatchNow on UroToday to learn more > https://t.co/FzLuRTa5ik
Commented in EUO on RAMPP trial:
• 💊 Limited modern systemic Tx
• 🔍 Stage-migration with PSMA PET
• ⏸️ Early stop → underpowered CSM signal
• ⚠️ Higher morbidity vs RT
➡️ 🎯 RT remains the most evidence-based local option in oligometastatic HSPC.
@ConstanceHuck, @AlbertoBossial
⚠️RAMPP trial :
🔑 If Local control of the primary tumor is beneficial, The optimal modality remains undefined!
🔑 RT currently represents the evidence-based, less morbid SOC until randomized data demonstrate otherwise
https://t.co/FHRAXPgFqF
🧪 Progress for bladder-sparing in MIBC:
An international consensus standardizes clinical complete response (cCR) and endorses event-free survival (EFS) as the key endpoint for next-gen perioperative trials.
#BladderCancer@JCO_ASCO
https://t.co/TkRRORlEIi
What the best approach for BCG-unresponsive NMIBC ?
If you are worried about the expenses like Donald Trump or @MRoupret, think about Radiation Therapy like @Achard_Verane !! #focus2025
GU005 allowed hotspots of 38.7 Gy. PACE-B allowed hotspots of 48-50 Gy.
So there is a 13 Gy eqd2 difference even between prescription doses and even more when accounting for hotspots.
Thus GU005 had a bit more BCR but lower tox. PACE-B had a little better BCR and more tox.
Just dose
💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo:
🔹 RT (n=77) vs Obs (n=76)
🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006)
🔹OS trend ↑RT (68% vs 57%), not sig
🔹No ↑ severe late adverse events
👉Adjuvant RT ↑ control & DFS, esp T3/4 & N+ pts. #ASTRO25 #RadOnc
#astro25@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
✨Our '' rising '' star, @ConstanceHuck
discussing TMT in the context of CIS, with @UroDocAsh.
👂Listen this excellent discussion here @urotoday
following the paper published in @EUplatinum
https://t.co/loh4kbsQU1
📫 Interim results of #Sunrise4 are released @TheLancetOncol
Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC
✅ TAR200+CET: pCR 42%, Major path Response 60%
✅ in cT2 pts baseline: pCR 48%
✅ TAR200 exposure-response association: pCR 50% if TAR200x4 full cycles
Can we cure selected pts with MIBC with intravesical Rx + single agent IO?
Future: is there a way to avoid #radicalcystectomy by consolidating Response with TAR200 in selected pts?
Primary results with full biomarker results are awaited
@Larvol@ASCO@myESMO@OncoAlert@urotoday@Medscape@SanRaffaeleMI@MyUniSR@JNJNews@spsutkaMD@DrFelixGuerrero@evanguelosx@BenjaminPradere
#bladdercancer #clinicalresearch #MedTwitter #neoadjuvant
https://t.co/5qsL8sAxWr
New insights on SBRT in recurrent ovarian cancer – now in CTRO:
“SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review”
👉 https://t.co/AbnJgiAnoH
🎯 Local control
⏳ Delayed systemic therapy
⚖️ Personalized strategy
@EORTC
📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence.
🚨Meta-analysis of 43 studies (n=8,119)
⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy@drMPerera + team @Uroweb!
➡️link https://t.co/VYvAn6kli1
EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al
Read the full update here: https://t.co/v6Z01NXKdr
#UroSoMe#MedTwitter#EurUrol #EAUGuidelines #GuidelinesUpdate